TY - JOUR
T1 - Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer
AU - Welslau, Manfred
AU - Müller, Volkmar
AU - Lüftner, Diana
AU - Schütz, Florian
AU - Stickeler, Elmar
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Thomssen, Christoph
AU - Witzel, Isabell
AU - Fehm, Tanja N
AU - Belleville, Erik
AU - Bader, Simon
AU - Seitz, Katharina
AU - Untch, Michael
AU - Thill, Marc
AU - Tesch, Hans
AU - Ditsch, Nina
AU - Lux, Michael P
AU - Aktas, Bahriye
AU - Banys-Paluchowski, Maggie
AU - Schneeweiss, Andreas
AU - Harbeck, Nadia
AU - Würstlein, Rachel
AU - Hartkopf, Andreas D
AU - Wöckel, Achim
AU - Seliger, Barbara
AU - Massa, Chiara
AU - Kolberg, Hans-Christian
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2022/6
Y1 - 2022/6
N2 - Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.
AB - Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.
U2 - 10.1055/a-1811-6106
DO - 10.1055/a-1811-6106
M3 - Journal articles
C2 - 35903719
SN - 0016-5751
VL - 82
SP - 580
EP - 589
JO - Geburtshilfe und Frauenheilkunde
JF - Geburtshilfe und Frauenheilkunde
IS - 6
ER -
